Combination immunotherapy and photodynamic therapy for cancer

Michael R. Hamblin, Ana P. Castano, Pawel A Mroz

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

Cancer is a leading cause of death among modern people largely due to metastatic disease. The ideal cancer treatment should target both the primary tumor and the metastases with minimal toxicity towards normal tissue. This is best accomplished by priming the body's immune system to recognize the tumor antigens so that after the primary tumor is destroyed, distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species leading to vascular shutdown and tumor cell death. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, generation of tumor-specific antigens, and induction of heat-shock proteins. Combination regimens using PDT and immunostimulating treatments are likely to even further enhance post-PDT immunity. These immunostimulants are likely to include products derived from pathogenic microorganisms that are effectively recognized by Toll-like receptors and lead to upregulation of transcription factors for cytokines and inflammatory mediators. The following cascade of events causes activation of macrophages, dendritic and natural killer cells. Exogenous cytokine administration can be another way to increase PDT-induced immunity as well as treatment with a low dose of cyclophosphamide that selectively reduces T-regulatory cells. Although so far these combination therapies have only been used in animal models, their use in clinical trials should receive careful consideration.

Original languageEnglish (US)
Title of host publicationProceedings of SPIE - The International Society for Optical Engineering
Volume6087
DOIs
StatePublished - May 8 2006
Externally publishedYes
EventBiophotonics and Immune Responses - San Jose, CA, United States
Duration: Jan 23 2006Jan 24 2006

Other

OtherBiophotonics and Immune Responses
CountryUnited States
CitySan Jose, CA
Period1/23/061/24/06

Fingerprint

Photodynamic Therapy
Immunotherapy
Photodynamic therapy
Tumors
Tumor
therapy
Cancer
tumors
cancer
immunity
Immunity
Cytokines
Metastasis
metastasis
antigens
Antigens
death
Cell
Immunologic Adjuvants
Likely

Keywords

  • Anti-tumor immunity
  • Antigen presentation
  • Cytotoxic T-cells
  • Dendritic cells
  • Photodynamic therapy
  • T regulatory cells
  • Toll-like receptors

Cite this

Hamblin, M. R., Castano, A. P., & Mroz, P. A. (2006). Combination immunotherapy and photodynamic therapy for cancer. In Proceedings of SPIE - The International Society for Optical Engineering (Vol. 6087). [608702] https://doi.org/10.1117/12.646275

Combination immunotherapy and photodynamic therapy for cancer. / Hamblin, Michael R.; Castano, Ana P.; Mroz, Pawel A.

Proceedings of SPIE - The International Society for Optical Engineering. Vol. 6087 2006. 608702.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Hamblin, MR, Castano, AP & Mroz, PA 2006, Combination immunotherapy and photodynamic therapy for cancer. in Proceedings of SPIE - The International Society for Optical Engineering. vol. 6087, 608702, Biophotonics and Immune Responses, San Jose, CA, United States, 1/23/06. https://doi.org/10.1117/12.646275
Hamblin MR, Castano AP, Mroz PA. Combination immunotherapy and photodynamic therapy for cancer. In Proceedings of SPIE - The International Society for Optical Engineering. Vol. 6087. 2006. 608702 https://doi.org/10.1117/12.646275
Hamblin, Michael R. ; Castano, Ana P. ; Mroz, Pawel A. / Combination immunotherapy and photodynamic therapy for cancer. Proceedings of SPIE - The International Society for Optical Engineering. Vol. 6087 2006.
@inproceedings{8e948b56e0bd4296b4a169d8ec94f251,
title = "Combination immunotherapy and photodynamic therapy for cancer",
abstract = "Cancer is a leading cause of death among modern people largely due to metastatic disease. The ideal cancer treatment should target both the primary tumor and the metastases with minimal toxicity towards normal tissue. This is best accomplished by priming the body's immune system to recognize the tumor antigens so that after the primary tumor is destroyed, distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species leading to vascular shutdown and tumor cell death. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, generation of tumor-specific antigens, and induction of heat-shock proteins. Combination regimens using PDT and immunostimulating treatments are likely to even further enhance post-PDT immunity. These immunostimulants are likely to include products derived from pathogenic microorganisms that are effectively recognized by Toll-like receptors and lead to upregulation of transcription factors for cytokines and inflammatory mediators. The following cascade of events causes activation of macrophages, dendritic and natural killer cells. Exogenous cytokine administration can be another way to increase PDT-induced immunity as well as treatment with a low dose of cyclophosphamide that selectively reduces T-regulatory cells. Although so far these combination therapies have only been used in animal models, their use in clinical trials should receive careful consideration.",
keywords = "Anti-tumor immunity, Antigen presentation, Cytotoxic T-cells, Dendritic cells, Photodynamic therapy, T regulatory cells, Toll-like receptors",
author = "Hamblin, {Michael R.} and Castano, {Ana P.} and Mroz, {Pawel A}",
year = "2006",
month = "5",
day = "8",
doi = "10.1117/12.646275",
language = "English (US)",
isbn = "0819461296",
volume = "6087",
booktitle = "Proceedings of SPIE - The International Society for Optical Engineering",

}

TY - GEN

T1 - Combination immunotherapy and photodynamic therapy for cancer

AU - Hamblin, Michael R.

AU - Castano, Ana P.

AU - Mroz, Pawel A

PY - 2006/5/8

Y1 - 2006/5/8

N2 - Cancer is a leading cause of death among modern people largely due to metastatic disease. The ideal cancer treatment should target both the primary tumor and the metastases with minimal toxicity towards normal tissue. This is best accomplished by priming the body's immune system to recognize the tumor antigens so that after the primary tumor is destroyed, distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species leading to vascular shutdown and tumor cell death. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, generation of tumor-specific antigens, and induction of heat-shock proteins. Combination regimens using PDT and immunostimulating treatments are likely to even further enhance post-PDT immunity. These immunostimulants are likely to include products derived from pathogenic microorganisms that are effectively recognized by Toll-like receptors and lead to upregulation of transcription factors for cytokines and inflammatory mediators. The following cascade of events causes activation of macrophages, dendritic and natural killer cells. Exogenous cytokine administration can be another way to increase PDT-induced immunity as well as treatment with a low dose of cyclophosphamide that selectively reduces T-regulatory cells. Although so far these combination therapies have only been used in animal models, their use in clinical trials should receive careful consideration.

AB - Cancer is a leading cause of death among modern people largely due to metastatic disease. The ideal cancer treatment should target both the primary tumor and the metastases with minimal toxicity towards normal tissue. This is best accomplished by priming the body's immune system to recognize the tumor antigens so that after the primary tumor is destroyed, distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the tumor with red light producing reactive oxygen species leading to vascular shutdown and tumor cell death. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, generation of tumor-specific antigens, and induction of heat-shock proteins. Combination regimens using PDT and immunostimulating treatments are likely to even further enhance post-PDT immunity. These immunostimulants are likely to include products derived from pathogenic microorganisms that are effectively recognized by Toll-like receptors and lead to upregulation of transcription factors for cytokines and inflammatory mediators. The following cascade of events causes activation of macrophages, dendritic and natural killer cells. Exogenous cytokine administration can be another way to increase PDT-induced immunity as well as treatment with a low dose of cyclophosphamide that selectively reduces T-regulatory cells. Although so far these combination therapies have only been used in animal models, their use in clinical trials should receive careful consideration.

KW - Anti-tumor immunity

KW - Antigen presentation

KW - Cytotoxic T-cells

KW - Dendritic cells

KW - Photodynamic therapy

KW - T regulatory cells

KW - Toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=33646198173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646198173&partnerID=8YFLogxK

U2 - 10.1117/12.646275

DO - 10.1117/12.646275

M3 - Conference contribution

SN - 0819461296

SN - 9780819461292

VL - 6087

BT - Proceedings of SPIE - The International Society for Optical Engineering

ER -